We provide support for research to find a personalised treatment against cancer

We back several leading scientific research projects against cancer.

Our aim is to cooperate on projects to improve treatment of the disease and offer patients better therapeutic options.

UITM - ”la Caixa” Molecular Cancer Therapy Research Unit. Vall d’Hebron Oncology Institute (VHIO)

The UITM - ”la Caixa” Molecular Cancer Therapy Research Unit at the VHIO, which opened in 2012, carries out clinical tests with drugs in the initial stages of development (phase I, phase II and phase III), and concentrates on new therapeutic targets for cancer treatment.

The UITM conducts molecular analysis of patients’ tumours in order to choose the right treatment, taking us a step closer to personalised medicine.

”la Caixa” International Program for Cancer Research and Education & International Meetings Program. MSKCC & VHIO

This programme was set up to help the Vall d’Hebron Oncology Institute (VHIO) and the Memorial Sloan Kettering Cancer Center (MSKCC) to expand their joint dissemination activities through research scholarships and international research meetings, building up the complementary strengths of the VHIO and MSKCC in the fields of basic research into cancer and the pursuit of medication, diagnostics and clinical studies.

Lung cancer research project. Catalan Oncology Institute (ICO)

This research project has helped to improve the treatment of tumours involving alteration of the EGFR gene and to understand why some become resistant to standard treatments.

This study is led by doctor Rafael Rosell, a European leader in the struggle against lung cancer and one of the pioneers of molecular studies of lung tumours to seek a personalised treatment.

“Epigenetic prediction of the response to drugs to select and optimise cancer therapy”, Epigenetics and Cancer Biology Programme (PEBC). Bellvitge Biomedical Research Institute (IDIBELL)

With the help of the ”la Caixa” foundation, doctor Manel Esteller, director of the Epigenetics and Cancer Biology Programme (PEBC) at the Bellvitge Biomedical Research Institute (IDIBELL), is carrying out a pioneering study of the epigenetic prediction of the response to drugs to optimise cancer therapy in patients who no longer respond to standard treatments.

This research sets out to define DNA methylation markers in colon, lung, pancreas and brain cancer cell lines, in order to predict their response to new treatments.

The results of the research will directly benefit a hundred patients taking part in the clinical project and will be the key to applying the right treatment to each patient in order to prolong and improve the quality of their life and reduce the impact of the toxicity of the treatment.

Josep Carreras Leukaemia Research Institute (IJC)

The Josep Carreras Leukaemia Research Institute (IJC) is the first European research centre focused exclusively on leukaemia and other malignant haematological illnesses and one of the few anywhere in the world.

The contribution of the ”la Caixa” Foundation to the Josep Carreras Foundation is used to foster the pursuit of projects and the purchase of laboratory equipment for the research groups.

“Immunotherapy based on the use of dendritic cells in advanced solid tumours in adolescents”, “Children Against Cancer” programme.  Navarra University Clinic

Led by doctor Ana Patiño García, director of the Clinical Genetics Unit at the Navarra University Clinic, this project is part of the “Children Against Cancer” programme. The aim is to improve survival rates and quality of life for children with advanced solid tumours and assess the safety of the treatment and the biological efficacy of the vaccine by means of in vitro studies.

The aim is to reduce mortality, predict the development of metastasis and develop efficient, non-toxic new therapies to stop paediatric oncology patients becoming adults with chronic diseases due to the treatment they have received.

“Interaction of DNA with Ru organometallic compounds and atomic quantum clusters.” University of Burgos and University of Santiago

The primary goal of this project is to find new anti-tumour drugs. With the aim of providing better therapeutic options for patients, new drugs are researched and developed, studying certain synthetic substances containing metals and assessing how they act together with biological molecules.

“Gene therapy for Dravet syndrome. Multiorganic metastasis mechanisms in autochthonous lung cancer models for personalised medicine.” Applied medical Research Centre (CIMA), University of Navarra

Dravet syndrome is one of the most serious epileptic encephalopathies in children. It is characterised by frequent, long-lasting convulsions which appear between the ages of four and six months in apparently healthy children and are associated with subsequent intellectual deterioration and behaviour disorders. There is currently no specific treatment and the habitual treatment for epilepsy makes the symptoms worse.

The aim of this project, led by doctor Gloria González-Aseguinolaza, are to analyse how this illness responds to gene therapy and to establish the parameters for getting clinically significant results.